The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Mini-dose methotrexate plus methylprednisolone for patients with aGvHD: Results from a phase III trial
|
Results from a phase III trial (NCT04960644) evaluating the safety and efficacy of mini-dose methotrexate combined with corticosteroids for the treatment of patients with acute graft-versus-host disease (aGvHD) were published in BMC Medicine by Wang, et al.1 Patients aged 15–65 years with previously untreated aGvHD were randomized 1:1 to receive either mini-dose methotrexate (MTX) plus methylprednisolone (MTX group, n = 78) or methylprednisolone alone (control group, n = 79).1 |
| Key learnings: |
|
The study met its primary endpoint of overall response rate on Day 10 (97% vs 81% in the MTX vs control group; p = 0.005), suggesting that mini-dose MTX plus methylprednisolone could be a viable option to enhance early treatment responses in patients with aGvHD. |
|
Additionally, the 1-year estimated failure-free survival rate was improved in the MTX vs control group (69% vs 41%; p = 0.002). |
|
Mini-dose MTX plus methylprednisolone was well tolerated, and incidences of cytopenias and mucositis were similar between groups. |
|
These findings, of improved efficacy and a tolerable safety profile compared with corticosteroids alone, support the integration of mini-dose MTX plus corticosteroids into clinical practice for the management of aGVHD and highlight a potential pathogenesis-oriented therapeutic approach. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
